Quantbot Technologies LP Purchases 8,352 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Quantbot Technologies LP increased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 7.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 119,533 shares of the company’s stock after purchasing an additional 8,352 shares during the period. Quantbot Technologies LP’s holdings in Amneal Pharmaceuticals were worth $947,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMRX. JPMorgan Chase & Co. raised its stake in shares of Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Barclays PLC lifted its holdings in Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock worth $2,466,000 after buying an additional 169,756 shares during the period. State Street Corp grew its position in shares of Amneal Pharmaceuticals by 3.8% in the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company’s stock worth $29,242,000 after buying an additional 127,753 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $520,000. Finally, Geode Capital Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 11.1% during the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after acquiring an additional 378,136 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $8.53 on Wednesday. The company has a market capitalization of $2.64 billion, a PE ratio of -12.54 and a beta of 1.05. The business has a fifty day moving average price of $8.41 and a 200-day moving average price of $8.37. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $730.52 million during the quarter, compared to analysts’ expectations of $708.21 million. During the same period last year, the firm posted $0.14 earnings per share. On average, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMRX. Barclays increased their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 17,410 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now directly owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company’s stock, valued at $405,628,045.15. The trade was a 9.33 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,240,000 shares of company stock worth $43,754,000 over the last quarter. 26.56% of the stock is currently owned by insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.